Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHES0815A in HER2-Positive Breast Cancer
NCT03451162Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of DHES0815A in HER2-positive breast cancer (2 arms), sponsored by Genentech. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs), Number of Participants With Dose-limiting Toxicity (DLT) and 3 more. Started Apr 2018; status: completed.
02
Drugs
DHES0815A
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03451162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451162.